IBIO
Live / Registered — Registered (as of 24 Sept 2024)
What this means for you
Registered since 24 Sept 2024. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 98091758
- Registration number
- 7511691
- Mark type
- Design + words
- Filed
- 19 Jul 2023
- Published for opposition
- 09 Jul 2024
- Registered
- 24 Sept 2024
- Attorney of record
- Daniel Chalker
Goods and services
- Class 042 — Scientific and technological services: Pharmaceutical peptide, protein, antibody, and chimeric antibody or protein drug development services; Pharmaceutical peptide, protein, antibody, and chimeric antibodies or proteins product development; Pharmaceutical research and development of peptides, proteins, antibodies, and chimeric antibodies or proteins; Conducting early evaluations in the field of new peptide, protein, antibody, and chimeric antibody or protein based pharmaceuticals; Development of peptide, protein, antibody, and chimeric antibody or protein based pharmaceutical preparations and medicines; Laboratory peptide and protein based research services relating to pharmaceuticals; Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; Providing medical and scientific research information in the fields of pharmaceuticals and genetics; Research and development of peptide, protein, antibody, and chimeric antibody or protein based pharmaceuticals for the treatment of age-related diseases and cancer; Research in the field of peptide, protein, antibody, and chimeric antibody or protein based pharmaceuticals; Research on the subject of peptide, protein, antibody, and chimeric antibody or protein based pharmaceuticals; Technical research in the field of peptide, protein, antibody, and chimeric antibody or protein based pharmaceutical studies; Testing, inspection or research of pharmaceuticals, cosmetics or foodstuff made with peptides, proteins, antibodies, and chimeric antibodies or proteins; Research and development in the pharmaceutical and biotechnology fields; Research and development regarding pharmaceuticals, proteins, and antibodies; platform-as-a-service (PaaS) featuring computer software platforms for protein analysis and discovery of antibody-based drugs; Software as a service (SAAS) services featuring software for designing molecule libraries for the purposes of generating products in the field of pharmaceuticals, biotechnology, and medicine; Computer software development in the field of artificial intelligence, biotechnology, pharmaceuticals, and medical applications; Laboratory research services relating to pharmaceuticals; Medical and scientific research in the field of cancer treatment and diagnosis; Providing information on the subject of scientific research in the field of biochemistry and biotechnology; Providing on-line non-downloadable software using artificial intelligence for use in facilitating product development in the field of biotechnology, pharmaceuticals, and medicine; Scientific research for medical purposes in the area of cancerous diseases; Software as a service (SAAS) services featuring software using artificial intelligence for use in facilitating product development in the field of biotechnology, pharmaceuticals, and medicine; Technical consulting in the field of pharmaceutical studies; Technology consultation in the field of artificial intelligence; Testing of pharmaceuticals; Testing, inspection or research of pharmaceuticals, cosmetics or foodstuff; Providing medical testing services and information in the field of cancer research and disease classification; Providing information about medical research in the field of artificial intelligence, medical biotechnology, and pharmaceuticals
Owner
Prior registrations
Prosecution history
- 24 Sept 2024 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
- 24 Sept 2024 — REGISTERED-PRINCIPAL REGISTER
- 09 Jul 2024 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 09 Jul 2024 — PUBLISHED FOR OPPOSITION
- 19 Jun 2024 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 30 May 2024 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 26 Apr 2024 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 26 Apr 2024 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 26 Apr 2024 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 08 Apr 2024 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 08 Apr 2024 — NON-FINAL ACTION E-MAILED
- 08 Apr 2024 — NON-FINAL ACTION WRITTEN
- 25 Mar 2024 — ASSIGNED TO EXAMINER
- 28 Dec 2023 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 28 Dec 2023 — CORRESPONDENCE RECEIVED IN LAW OFFICE